Join us in celebrating 
World IBD Day 2025!

Activities


Filtering by: “EFCCA Patient Talks”

EFCCA Talk: "Living with Fibrosis: Challenges, Treatments and Innovations"
Feb
6

EFCCA Talk: "Living with Fibrosis: Challenges, Treatments and Innovations"

On 6 February 2025, EFCCA brought together top researchers, industry experts and patient advocates for a webinar on intestinal fibrosis in IBD—an issue that too often gets overlooked. This session was part of the FIBROTARGET project (Horizon Europe), which is working to improve the prevention, diagnosis, and treatment of fibrosis and fibrostenosis in IBD.

View Event →
EFCCA Patient Talk 3: Seasonal vaccines and IBD
Nov
27

EFCCA Patient Talk 3: Seasonal vaccines and IBD

Within the framework of our EFCCA Patient Talk series we are pleased to announce our next Patient Talk to take place on Friday 27 November 2020 from 3-4 pm. It will look at the topic of Seasonal vaccines and IBD following a survey that EFCCA had carried out amongst its members concerning the availability and practise of seasonal vaccines during our current pandemic.

View Event →
Catch your dream summer camp
Feb
15
to 18 Feb

Catch your dream summer camp

The European Summer Camp, or “ESC”, project ran in 2010 and 2011. Two international summer camps with the motto “Catch Your Dream” were organized by EFCCA and the EFCCA Youth Group in the Netherlands, and they gathered together dozens of young people with Inflammatory Bowel Disease (IBD) from European countries. 

View Event →
Patient Safety: Biologics and Biosimilars
Feb
4
to 11 Nov

Patient Safety: Biologics and Biosimilars

Since about 2015 the issue on biologics and biosimilars has received a lot of attention from the medical, regulatory and patient community. Licensing rights of biological medicines used in the treatment not only of IBD but also other autoimmune modulated diseases are coming to an end and biosimilars medicines are being developed to compete with original biological treatment options. In various countries in the EU and elsewhere biosimilars have already entered the market.  

View Event →